TSP1040-CMap - carcinogenome project: Toxicogenomic signatures after exposure to 2,2',5,5'-tetrachlorobenzidine


TSA8822-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine


TSA9014-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to 2,2',5,5'-tetrachlorobenzidine


TSA9135-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to 2,2',5,5'-tetrachlorobenzidine


TSA9256-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to 2,2',5,5'-tetrachlorobenzidine


TSF10132-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 40.0 µM


1 subfactor(s)
TSF10133-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 20.0 µM


1 subfactor(s)
TSF10134-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 10.0 µM


1 subfactor(s)
TSF10135-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 5.0 µM


1 subfactor(s)
TSF10136-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 2.5 µM


1 subfactor(s)
TSF10137-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 1.25 µM


1 subfactor(s)
TSF10773-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 100.97 µM


1 subfactor(s)
TSF10774-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


1 subfactor(s)
TSF10775-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM


1 subfactor(s)
TSF11125-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


1 subfactor(s)
TSF11126-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM


1 subfactor(s)
TSF11473-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


1 subfactor(s)
TSF11474-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM


1 subfactor(s)
TSF11825-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to 2,2',5,5'-tetrachlorobenzidine 100.97 µM


1 subfactor(s)
TSF11826-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


1 subfactor(s)
TSF11827-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM


1 subfactor(s)
TSS10133-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 40.0 µM


TSS10134-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 20.0 µM


TSS10135-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 10.0 µM


TSS10136-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 5.0 µM


TSS10137-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 2.5 µM


TSS10138-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 1.25 µM


TSS10774-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 100.97 µM


TSS10775-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


TSS10776-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM


TSS11126-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


TSS11127-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM


TSS11474-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


TSS11475-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM


TSS11826-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to 2,2',5,5'-tetrachlorobenzidine 100.97 µM


TSS11827-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to 2,2',5,5'-tetrachlorobenzidine 33.66 µM


TSS11828-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A after exposure to 2,2',5,5'-tetrachlorobenzidine 11.22 µM



TSP1040 - CMap - carcinogenome project: Toxicogenomic signatures after exposure to 2,2',5,5'-tetrachlorobenzidine Public


In the chemical selection process, we prioritized chemicals with long-term rodent liver carcinogenicity annotation for inclusion in this experiment. Long-term carcinogenicity annotations were derived from the Carcinogenic Potency Database (CPDB) (Fitzpatrick 2008). Additional chemicals without carcinogenicity annotation were included on the basis of interest to the Superfund Research Program (environmental toxicants), presence in controversial commercial products (included for predictive purposes), and evidence of binding to the aryl hydrocarbon receptor (AhR), as the AhR is an important mediator of xenobiotics, including carcinogens. In total, 330 unique chemicals were used in the analysis, including 128 carcinogens, 168 noncarcinogens, 100 genotoxicants, and 161 nongenotoxicants. (Li et al., 2019) Liver Carcinogenicitynon-carcinogen Liver Genotoxicitygenotoxic Breast Carcinogenicitynon-carcinogen Breast Genotoxicitygenotoxic

Experimental design


No experimental design provided

Results


No results provided